Case Study:
Faster Time to Reimbursement
How to Use AI for Faster Time to Reimbursement
According to Pharmaceutic Executive, a delay in launch can cost a company an average of $15 million per drug, per day. This project was about using Artificial Intelligence to speed up the time to reimbursement on different formularies after FDA approval.
The Client Problem
Thee client analysed how many $ were left on the table with every day delay to reimbursement approval in different formularies. They wanted to see if Artificial Intelligence could impact this positively and speed up time to reimbursement thereby increasing revenue from their products.
The Solution
Using a combination of different AI techniques, to:
- identify the factors affecting time-to-reimbursement for newly launched medicines post market approval,
- provide insight into what to include in, or leave out of submissions for formulary inclusion
- find other important considerations and insights that have worked in the past to accelerate time-to-reimbursement.
The Outcome
Reimbursement was achieved much faster in the pilot of formularies using AI versus the ones not using AI. The average improvement in speed was 6 weeks. At an average of $15 m/day that can be left on the table, the amount of revenue gained from this simple increase in speed to reimbursement allowed a significant return on investment and the approach is now being rolled out to other products as well.
To achieve these kinds of results, contact Eularis today.
Latest Blogs
Check out our latest blogs
The Future of AI Is Living Intelligence – Here’s Why You Need It
What Is Living Intelligence in AI and Why Does It Matter for the Future? In the rapidly changing world of pharmaceuticals today, AI systems that
Artificial Intelligence is on the C Suite Agenda – but Ineffectively Implemented
It is good to finally see that big data and Artificial Intelligence analytics are now on the pharma C-Suite agenda with a recent survey by NewVantage Partners showing that 85.5% of major corporations are working on big data initiatives. This is because many companies have now measured and proven the value of these for growing their pharma brands and companies.
AI + Smart Devices: The New Frontline Against Chronic Disease
Chronic diseases have emerged as one of the most significant public health challenges of the 21st century. According to the World Health Organization, chronic diseases